Objective: Hyperhomocysteinemia (HHcy) has been identified as an independent risk factor for atherosclerotic vascular disease. The effect of high-dose folic acid or combination vitamin therapy for the treatment of HHcy on the microcirculation is unknown. The purpose of this study was to evaluate the effect of a combination of folic acid, vitamin B6, and vitamin B12 on endothelium-dependent and endothelium-independent vasoreactivity in patientswith HHcy.
Methods: Baseline cutaneous microvascular vasoreactivity was measured in 20 patients with HHcy and 18 patients with normohomocysteinemia (NHcy). Laser Doppler scan imaging before and after iontophoresis of 1% acetylcholine chloride (endothelium-dependent response) and 1% sodium nitroprusside (endothelium-independent response) was performed for the measurement of forearm skin vasodilatation. Patients were then treated with 10 mg folic acid, 100 mg vitamin B6, and 1 mg vitamin B12 orally once a day for 6 months. Follow-up fasting serum homocysteine and cutaneous Laser Doppler scan imaging before and after iontophoresis were performed at 1, 2, 3, and 6 months. Statistical analysis was performed using Fisher's exact test, paired t test, and Wilcoxon matched-pairs signed-ranks test, with significance set at P < .05.
Results: The HHcy group was older than the NHcy group (70.89 ± 1.95 vs 61.78 ± 2.73 years, P = .02). Otherwise the groups were similar in terms of race, tobacco use, comorbid diseases, and serum lipoproteins. Over the 6-month period, fasting serum homocysteine levels decreased significantly in both the NHcy group (10.40 ± 0.59 µmol/L vs 8.97 ± 0.84 µmol/L, P = .01) and the HHcy group (19.80 ± 1.06 µmol/L vs 13.40 ± 0.86 µmol/L, P = .0002). There were no statistically significant changes in endothelium-independent vasoreactivity (voltage change from baseline) in either group. Endothelium-independent vasore activity decreased over the 6-month period in the HHcy group (0.20 ± 0.04 V vs 0.11 ± 0.03 V, P = .03). Subanalysis of HHcy with diabetes or age greater than 65 years both showed worsening trends in endothelium-independent vasoreactivity (P = .05 for both groups). There were no statistically significant changes in endothelium-independent vasoreactivity in the NHcy group.
Conclusions: High doses of folic acid and vitamins B6 and B12 lower fasting serum homocysteine levels in patients with HHcy. Older and diabetic patients with HHcy tend to do worse possibly because of long-term fixed microvascular insult secondary to multiple sustained comorbidities.
Clarke R., Daly L., Robinson K., et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med.1991;324:1149-1155.
2.
Tsai JC, Perrella MA, Yoshizumi M., et al. Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis. Proc Natl Acad Sci USA. 1994; 91:6369-6373.
3.
Carmody BJ, Arora S., Avena R., Cosby K., Sidawy ANFolic acid inhibits homocysteine-induced proliferation of human arterial smooth muscle cells. J Vasc Surg.1999;30:1121-1128.
4.
Haltmayer M. , Mueller T., Lange W., et al. Relation between homocysteine and non-fatal stroke in peripheral arterial disease. Eur J Neurol.2002;9:609-614.
5.
Nygard O., Nordrehaug JE, Refsum H., Ueland PM, Farstad M., Vollset SEPlasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med.1997;337:230-236.
6.
Vasan RS, Beiser A., D'Agostino RB, et al. Plasma homocysteine and risk for congestive heart failure in adults without prior myocardial infarction. JAMA.2003;289: 1251-1257.
7.
Bostom AG, Silbershatz H., Rosenberg IH, et al. Non-fasting plasma total homocysteine levels and all-cause and cardiovascular disease mortality in elderly Framing-ham men and women. Arch Intern Med.1999;159: 1077-1080.
8.
Homocysteine Lowering Trialists' Collaboration.Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials. BMJ.1998 ;316:894—898.
9.
Woo KS, Chook P., Chan LL, et al. Long-term improvement in homocysteine levels and arterial endothelial function after 1-year folic acid supplementation. Am J Med.2002;112:535-539.
10.
Chambers JC , Ueland PM, Obeid OA, Wrigley J., Refsum H., Kooner JSImproved vascular endothelial function after oral B vitamins: an effect mediated through reduced concentrations of free plasma homocysteine. Circulation. 2000;102:2479-2483.
11.
Thambyrajah J., Landray MJ, Jones HJ, McGlynn FJ, Wheeler DC, Townend JNA randomized double-blind placebo-controlled trial of the effect of homocysteine-lowering therapy with folic acid on endothelial function in patients with coronary artery disease. J Am Coll Cardiol.2001;37:1858-1863.
12.
Pullin CH, Ashfield-Watt PA, Burr ML, et al. Optimization of dietary folate or low-dose folic acid supplements lower homocysteine but do not enhance endothelial function in healthy adults, irrespective of the methylenetetrahydrofolate reductase (C677T) genotype. J Am Coll Cardiol.2001;38:1799-1805.
13.
van Dijk RA , Rauwerda JA, Steyn M., Twisk JW, Stehouwer CDLong-term homocysteine-lowering treatment with folic acid plus pyridoxine is associated with decreased blood pressure but not with improved brachial artery endothelium-dependent vasodilation or carotid artery stiffness: a 2-year, randomized, placebo-controlled trial. Arterioscler Thromb Vasc Biol.2001;21:2072-2079.
14.
Carlsson CM , Pharo LM, Aeschlimann SE, Mitchell C., Underbakke G., Stein JHEffects of multivitamins and low-dose folic acid supplements on flow-mediated vasodilation and plasma homocysteine levels in older adults. Am Heart J.2004;148:E11.
15.
Holven KB, Holm T., Aukrust P., et al. Effect of folic acid treatment on endothelium-dependent vasodilation and nitric oxide-derived end products in hyperhomocysteinemic subjects. Am J Med.2001;110:536-542.
16.
Mangoni AA, Sherwood RA, Swift CG, Jackson SHFolic acid enhances endothelial function and reduces blood pressure in smokers: a randomized controlled trial. J Intern Med.2002;252:497-503.
17.
Finkelstein JDPathways and regulation of homocysteine metabolism in mammals. Semin Thromb Hemost. 2000;26:219-225.
18.
Beaulieu AJ , Gohh RY, Han H., et al. Enhanced reduction of fasting total homocysteine levels with supraphysiological versus standard multivitamin dose folic acid supplementation in renal transplant recipients. Arterioscler Thromb Vasc Biol. 1999;19:2918-2921.
19.
Selhub J., Jacques PF, Wilson PW, Rush D., Rosenberg IHVitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA.1993;270:2693-2698.
20.
McKinley MC , McNulty H., McPartlin J., et al. Low-dose vitamin B-6 effectively lowers fasting plasma homocysteine in healthy elderly persons who are folate and riboflavin replete. Am J Clin Nutr.2001;73:759-764.
21.
Abularrage CJ, Sidawy AN, Aidinian G., Singh N., Weiswasser JM, Arora S.Evaluation of the microcirculation in vascular disease. J Vasc Surg.2005;42:574-581.
22.
Glynn SA, Albanes D.Folate and cancer: a review of the literature. Nutr Cancer.1994;22:101-119.
23.
Ingrosso D. , Cimmino A., Perna AF, et al. Folate treatment and unbalanced methylation and changes of allelic expression induced by hyperhomocysteinaemia in patients with uraemia. Lancet. 2003;361:1693-1699.
24.
Lange H., Suryapranata H., De Luca G., et al. Folate therapy and in-stent restenosis after coronary stenting . N Engl J Med.2004;350:2673-2681.
25.
Baker F., Picton D., Blackwood S., et al. Blinded comparison of folic acid and placebo in patients with ischemic heart disease: an outcome trial. Circulation. 2002; 106(S2):II-741.
